Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

User tried various hair loss treatments, now switching to Dut and hair transplant. Experienced side effects and plans to track them.

User shows wet hair and blow drying to prove no hair fibers used. Hair gains achieved with finasteride and minoxidil.

Microneedling the scalp can cause sneezing, runny nose, and watery eyes due to nerve stimulation, histamine release, reflex actions, or sinus relief. Several users experience similar symptoms.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The user has seen no regrowth after 1 year and 2 months on finasteride, despite increasing the dose, and is inquiring about the potential of future treatments like verteporfin and gt20029 for hair regrowth.

A 25-year-old shared progress pictures after using finasteride 1mg daily for 6 months and dutasteride 1.5mg daily for another 6 months, noting significant hair regrowth, especially in the temporal peaks, with no side effects. The user switched from finasteride to dutasteride for more effective treatment.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.

A 17-year-old is experiencing hair shedding and is concerned about a receding hairline, using hair products like powder and sea salt spray. Advice given includes maintaining good nutrition, ensuring hair products don't build up, and considering further resources if worried.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user is using finasteride 1.25mg three times a week for hair regrowth and reports no significant side effects except watery semen initially. They also use a local caffeine shampoo and are considering haircuts to improve appearance.

The post and conversation are about a user claiming to be 137 years old with a full head of hair. Specific treatments mentioned include dutasteride, RU58841, and minoxidil.

The user is seeing slow hair regrowth using Minoxidil, Finasteride, a derma roller, vitamins, and zinc. Some suggest switching to dutasteride or adding other treatments, but others doubt significant cosmetic improvement due to advanced hair loss.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses the benefits of combining scalp stem cell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.

The conversation discusses post-hair transplant care, specifically about removing scabs gently after a week, using Vitamin E oil. The user wonders if using harsher methods like steel wool would affect results, but others reassure that if there was no pain or bleeding, it's likely fine.

Hair loss discussion mentions using estrogen mixed with growth stimulants like oral minoxidil for scalp hair growth. Idea proposed for an artificial SARM-estrogen that only affects hair without body side effects.

The conversation discusses the effectiveness of Regenera Activia stem cells versus Cellgenic exosomes for hair loss treatment. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without results.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.